Array
(
[id] => 1711
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1711.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend using the following LMWH according to the dosing regimens indicated by the marketing authorization:enoxaparin 2000 IU x 1/day SC if eGFR is between 15 and 30 mL/min/1.73 m²tinzaparin 4500 IU x 1/day SC if eGFR is > 20 mL/min/1.73 m²（Evidence level:High；Recommendation grade:Strong）
[laiyuan] => 我们建议按照上市许可所标明的给药方案使用以下低分子量肝素：如果估算的肾小球滤过率在15至30 mL/min/1.73 m²之间，依诺肝素皮下注射，每日一次，每次2000IU；如果肾小球滤过率大于20 mL/min/1.73 m²，亭扎肝素皮下注射，每日一次，每次4500IU。（证据分级：高；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
我们建议按照上市许可所标明的给药方案使用以下低分子量肝素：如果估算的肾小球滤过率在15至30 mL/min/1.73 m²之间，依诺肝素皮下注射，每日一次，每次2000IU；如果肾小球滤过率大于20 mL/min/1.73 m²，亭扎肝素皮下注射，每日一次，每次4500IU。（证据分级：高；推荐强度：强推荐）
We recommend using the following LMWH according to the dosing regimens indicated by the marketing authorization:enoxaparin 2000 IU x 1/day SC if eGFR is between 15 and 30 mL/min/1.73 m²tinzaparin 4500 IU x 1/day SC if eGFR is > 20 mL/min/1.73 m²（Evidence level:High；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1712
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1712.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients with end-stage renal disease, we recommend using UFH at a dose of 5000 IU x 2/day SC, as other anticoagulants are not recommended.（Evidence level:High；Recommendation grade:Strong）
[laiyuan] => 对于终末期肾病患者，我们建议使用普通肝素，皮下注射，每日两次，每次5000IU，因为其他抗凝剂不建议使用。（证据分级：高；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于终末期肾病患者，我们建议使用普通肝素，皮下注射，每日两次，每次5000IU，因为其他抗凝剂不建议使用。（证据分级：高；推荐强度：强推荐）
For patients with end-stage renal disease, we recommend using UFH at a dose of 5000 IU x 2/day SC, as other anticoagulants are not recommended.（Evidence level:High；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1713
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1713.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients with class I or II obesity (BMI between 30 and 39 kg/m²) requiring pharmacological thromboprophylaxis, we suggest using a standard dosing regimen .（Evidence level:moderate/Low；Recommendation grade:Strong）
[laiyuan] => 对于需要进行药物性血栓预防的I级或II级肥胖（体重指数在30至39kg/m²之间）的患者，我们建议采用标准给药方案。（证据分级：中或低；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于需要进行药物性血栓预防的I级或II级肥胖（体重指数在30至39kg/m²之间）的患者，我们建议采用标准给药方案。（证据分级：中或低；推荐强度：强推荐）
For patients with class I or II obesity (BMI between 30 and 39 kg/m²) requiring pharmacological thromboprophylaxis, we suggest using a standard dosing regimen .（Evidence level:moderate/Low；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1714
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1714.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients with class III obesity and above (BMI ≥ 40 kg/m²)requiring pharmacological prophylaxis, we suggest the following dosing regimens according to thespecific indications for each anticoagulant:enoxaparin 4000 IU x 2/day subcutaneously. An increased dose of 6000 IU x 1/day is also considered. The 6000 IU x 2/day dose may be reserved for patients > 150 kg.dalteparin 5000 IU x 2/day subcutaneously tinzaparin 75 IU/kg (actual weight) x 1/day subcutaneously fondaparinux 5 mg x 1/day subcutaneously apixaban: 2.5 mg x 2/day orally.rivaroxaban: 10 mg x 1/day orally. There is little experience with direct anti-Xa DOACs for BMI > 50 kg/m² or weight > 150 kg.（Evidence level:moderate/Low；Recommendation grade:Strong）
[laiyuan] => 对于需要药物预防且为 Ⅲ 级及以上肥胖（体重指数≥40kg/m²）的患者，我们建议根据每种抗凝剂的具体适应证采用以下给药方案）：依诺肝素：皮下注射，每日两次，每次 4000 国际单位。也可考虑增加剂量为每日一次，每次 6000 IU。对于体重>150 千克的患者，可采用每日两次、每次 6000 IU的剂量。达肝素：皮下注射，每日两次，每次 5000 IU。亭扎肝素：按实际体重计算，皮下注射，每日一次，剂量为 75 IU/kg。磺达肝癸钠：皮下注射，每日一次，每次 5 毫克。阿哌沙班：口服，每日两次，每次2.5mg。利伐沙班：口服，每日一次，每次10mg。对于体重指数 >50kg/m²或体重 >150kg的患者，直接抗Xa因子直接口服抗凝剂的使用经验有限。（证据分级：中或低；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于需要药物预防且为 Ⅲ 级及以上肥胖（体重指数≥40kg/m²）的患者，我们建议根据每种抗凝剂的具体适应证采用以下给药方案）：依诺肝素：皮下注射，每日两次，每次 4000 国际单位。也可考虑增加剂量为每日一次，每次 6000 IU。对于体重>150 千克的患者，可采用每日两次、每次 6000 IU的剂量。达肝素：皮下注射，每日两次，每次 5000 IU。亭扎肝素：按实际体重计算，皮下注射，每日一次，剂量为 75 IU/kg。磺达肝癸钠：皮下注射，每日一次，每次 5 毫克。阿哌沙班：口服，每日两次，每次2.5mg。利伐沙班：口服，每日一次，每次10mg。对于体重指数 >50kg/m²或体重 >150kg的患者，直接抗Xa因子直接口服抗凝剂的使用经验有限。（证据分级：中或低；推荐强度：强推荐）
For patients with class III obesity and above (BMI ≥ 40 kg/m²)requiring pharmacological prophylaxis, we suggest the following dosing regimens according to thespecific indications for each anticoagulant:enoxaparin 4000 IU x 2/day subcutaneously. An increased dose of 6000 IU x 1/day is also considered. The 6000 IU x 2/day dose may be reserved for patients > 150 kg.dalteparin 5000 IU x 2/day subcutaneously tinzaparin 75 IU/kg (actual weight) x 1/day subcutaneously fondaparinux 5 mg x 1/day subcutaneously apixaban: 2.5 mg x 2/day orally.rivaroxaban: 10 mg x 1/day orally. There is little experience with direct anti-Xa DOACs for BMI > 50 kg/m² or weight > 150 kg.（Evidence level:moderate/Low；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1715
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1715.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients with class III obesity undergoing surgery with a high risk for VTE, we suggest combining IPC with pharmacological prophylaxis.（Evidence level:moderate/Low；Recommendation grade:Strong）
[laiyuan] => 对于患有Ⅲ级肥胖且接受静脉血栓栓塞症高风险手术的患者，我们建议将间歇性充气加压装置与药物预防措施相结合。（证据分级：中或低；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于患有Ⅲ级肥胖且接受静脉血栓栓塞症高风险手术的患者，我们建议将间歇性充气加压装置与药物预防措施相结合。（证据分级：中或低；推荐强度：强推荐）
For patients with class III obesity undergoing surgery with a high risk for VTE, we suggest combining IPC with pharmacological prophylaxis.（Evidence level:moderate/Low；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1716
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1716.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => After bariatric surgery, we suggest postoperative pharmacological thromboprophylaxis with LMWH or fondaparinux for a minimum of 10 days.（Evidence level:moderate/Low；Recommendation grade:Strong）
[laiyuan] => 在减肥手术后，我们建议术后使用低分子量肝素或磺达肝癸钠进行至少 10 天的药物性血栓预防。（证据分级：中或低；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
在减肥手术后，我们建议术后使用低分子量肝素或磺达肝癸钠进行至少 10 天的药物性血栓预防。（证据分级：中或低；推荐强度：强推荐）
After bariatric surgery, we suggest postoperative pharmacological thromboprophylaxis with LMWH or fondaparinux for a minimum of 10 days.（Evidence level:moderate/Low；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1717
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1717.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients with low body weight, we suggest adjusting dosing regimens accordingly.（Evidence level:moderate/Low；Recommendation grade:Strong）
[laiyuan] => 对于体重偏低的患者，我们建议相应地调整给药方案。（证据分级：中或低；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于体重偏低的患者，我们建议相应地调整给药方案。（证据分级：中或低；推荐强度：强推荐）
For patients with low body weight, we suggest adjusting dosing regimens accordingly.（Evidence level:moderate/Low；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1718
[catid] => 289
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1718.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that from puberty or the age of 14, pharmacological prophylaxis should follow the same recommendations as for adults. （Evidence level:moderate/Low；Recommendation grade:Strong）
[laiyuan] => 我们建议，从青春期或14岁起，药物预防应遵循与成年人相同的建议。（证据分级：中或低；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
我们建议，从青春期或14岁起，药物预防应遵循与成年人相同的建议。（证据分级：中或低；推荐强度：强推荐）
We suggest that from puberty or the age of 14, pharmacological prophylaxis should follow the same recommendations as for adults. （Evidence level:moderate/Low；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1719
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1719.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend using pharmacological prophylaxis in intensive care patients to reduce VTE complications.（Evidence level:High；Recommendation grade:Strong）
[laiyuan] => 我们建议对重症监护患者使用药物预防措施以减少静脉血栓栓塞症并发症。（证据分级：高；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
我们建议对重症监护患者使用药物预防措施以减少静脉血栓栓塞症并发症。（证据分级：高；推荐强度：强推荐）
We recommend using pharmacological prophylaxis in intensive care patients to reduce VTE complications.（Evidence level:High；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
Array
(
[id] => 1720
[catid] => 302
[title] => Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/1720.html
[link_id] => 0
[tableid] => 0
[inputip] => 39.144.210.1
[inputtime] => 2024-12-12 11:19:01
[updatetime] => 2024-12-12 11:19:01
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/39447869/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2024
[guojia] => Anaesthesia, critical care & pain medicine
[pdf] =>
[tjyjyw] =>
[lyyw] => In the absence of end-stage renal disease, we recommend LMWH at prophylactic doses over UFH.（Evidence level:High；Recommendation grade:Strong）
[laiyuan] => 在不存在终末期肾病的情况下，我们推荐使用预防剂量的低分子量肝素而非普通肝素。（证据分级：高；推荐强度：强推荐）
[znzldj] => B级
[_inputtime] => 1733973541
[_updatetime] => 1733973541
[_nrjc] =>
[_nrsh] =>
)
推荐意见
在不存在终末期肾病的情况下，我们推荐使用预防剂量的低分子量肝素而非普通肝素。（证据分级：高；推荐强度：强推荐）
In the absence of end-stage renal disease, we recommend LMWH at prophylactic doses over UFH.（Evidence level:High；Recommendation grade:Strong）
证据评价方法：GRADE
指南质量等级：B级
年份：2024
国家：Anaesthesia, critical care & pain medicine
